Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.7150/thno.46691 http://scihub22266oqcxt.onion/10.7150/thno.46691 32483428!7254986!32483428     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Theranostics 2020 ; 10 (13): 5932-5942 Nephropedia Template TP {{tp|p=32483428|t=2020. Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients |pdf=|usr=}}{{32483428}} gab.com Text Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients JO: Theranostics http://www.kidney.de/pget.php?&tw=1&pmid=32483428 #FOAvip On the 30(th) of January 2020, the World Health Organization fired up the sirens against a fast spreading infectious disease caused by a newly discovered Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and gave this disease the name COVID-19. While there is currently no specific treatment for COVID-19, several off label drugs approved for other indications are being investigated in clinical trials across the globe. In the last decade, theranostic nanoparticles were reported as promising tool for efficiently and selectively deliver therapeutic moieties (i.e. drugs, vaccines, siRNA, peptide) to target sites of infection. In addition, they allow monitoring infectious sides and treatment responses using noninvasive imaging modalities. While intranasal delivery was proposed as the preferred administration route for therapeutic agents against viral pulmonary diseases, NP-based delivery systems offer numerous benefits to overcome challenges associated with mucosal administration, and ensure that these agents achieve a concentration that is many times higher than expected in the targeted sites of infection while limiting side effects on normal cells. In this article, we have shed light on the promising role of nanoparticles as effective carriers for therapeutics or immune modulators to help in fighting against COVID-19. Twit Text FOAVip Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients ????Theranostics http://www.kidney.de/pget.php?&tw=1&pmid=32483428 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32483428 #FOAvip English Wikipedia <ref>{{Cite pmid|32483428}}</ref> Optimizing use of theranostic nanoparticles as a life-saving strategy for treating COVID-19 patients #MMPMID32483428 Itani R; Tobaiqy M; Al Faraj A Theranostics 2020[]; 10 (13): 5932-5942 PMID32483428show ga On the 30(th) of January 2020, the World Health Organization fired up the sirens against a fast spreading infectious disease caused by a newly discovered Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and gave this disease the name COVID-19. While there is currently no specific treatment for COVID-19, several off label drugs approved for other indications are being investigated in clinical trials across the globe. In the last decade, theranostic nanoparticles were reported as promising tool for efficiently and selectively deliver therapeutic moieties (i.e. drugs, vaccines, siRNA, peptide) to target sites of infection. In addition, they allow monitoring infectious sides and treatment responses using noninvasive imaging modalities. While intranasal delivery was proposed as the preferred administration route for therapeutic agents against viral pulmonary diseases, NP-based delivery systems offer numerous benefits to overcome challenges associated with mucosal administration, and ensure that these agents achieve a concentration that is many times higher than expected in the targeted sites of infection while limiting side effects on normal cells. In this article, we have shed light on the promising role of nanoparticles as effective carriers for therapeutics or immune modulators to help in fighting against COVID-19. |*Betacoronavirus/drug effects/genetics/immunology[MESH] |Administration, Intranasal[MESH] |Antiviral Agents/administration & dosage[MESH] |COVID-19[MESH] |COVID-19 Vaccines[MESH] |Coronavirus Infections/epidemiology/immunology/prevention & control/*therapy[MESH] |Drug Delivery Systems/methods[MESH] |Humans[MESH] |Nanoparticles/administration & dosage/chemistry/*therapeutic use[MESH] |Pandemics[MESH] |Pneumonia, Viral/epidemiology/immunology/*therapy[MESH] |RNA, Small Interfering/administration & dosage/genetics[MESH] |SARS-CoV-2[MESH] |Theranostic Nanomedicine/*methods[MESH] |Vaccines, Virus-Like Particle/administration & dosage[MESH] |Viral Vaccines/administration & dosage/immunology[MESH]Optimizing use of theranostic nanoparticles as a life-saving strategy (epmc).pdf DeepDyve Pubget Overpricing